Pink SheetThe US Food and Drug Administration has successfully helped pull stalled cell and gene therapy programs off the cutting room floor in recent years and wants sponsors who might benefit from the agency’
ScripPfizer’s recent exit from gene therapies was not an indictment of the safety and efficacy of gene and cellular therapies. Rather it was the latest example of the difficulties in commercializing these
Pink SheetRisk is inherent from both a financial and a clinical perspective when developing therapies for rare diseases – particularly if these are gene therapies. One way to bring these products to market is b
Pink SheetSeven new advanced therapy medicinal products (ATMPs) could be approved for pan-EU approval this year, based on data from the Pink Sheet’s EU regulatory filings tracker , including Roche / Sarepta